A survivor shares her personal journey with stage 2A breast cancer, from choosing a bilateral mastectomy to navigating ...
SunMo demonstrated superior progression-free survival and overall response for mosunetuzumab plus polatuzumab vedotin versus ...
Patients with early-stage bladder cancer are often able to maintain their usual routines. Some may experience urinary ...
Insurance companies deny cancer treatment claims for several reasons: a therapy may be deemed experimental or not yet ...
A breast cancer survivor shares the discovery of a new kidney mass and details how she will be a smarter, more assertive ...
Iza-bren improved survival and delayed disease progression versus chemotherapy in previously treated metastatic ...
Genotype-informed surveillance should pair colonoscopy with upper endoscopy when MLH1/MSH2 mutations or family history ...
Adding Opdivo (nivolumab) and Yervoy (ipilimumab) to chemotherapy did not improve how long patients with HER2-negative ...
RASolute 302 showed daraxonrasib reduced mortality risk by 60% versus chemotherapy in previously treated metastatic PDAC, with median OS 13.2 versus 6.7 months. OPTIMA found Prosigna-defined low-risk ...
Nurse-led ONS study identifies strategies to reduce CLABSI risk in hematologic cancer care through standardized workflows and documentation.
After losing his mother to colorectal cancer in 2009, Michael Sapienza turned unimaginable grief into action. Today, as CEO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results